Cellectar’s Iopofosine I 131 Earns Rare Pediatric Disease Designation, Shows Strong Survival Benefit in Aggressive Brain Tumors
FDA Designation Signals Hope for Relapsed Pediatric High-Grade Glioma Patients
Cellectar Biosciences announced a significant milestone with the U.S. Food and Drug Administration (FDA) granting Rare Pediatric Disease Designation (RPDD) for iopofosine I 131 in children with inoperable relapsed or refractory pediatric high-grade glioma (r/r pHGG). This marks a key recognition for a novel cancer-targeting radioconjugate agent aimed at one of the most difficult-to-treat cancers in young patients.
Clinical Data Show Meaningful Survival Gains Over Historical Benchmarks
Encouraging interim results from the ongoing CLOVER-2 Phase 1b trial highlight the therapeutic promise of iopofosine I 131. For context, published literature indicates that children with relapsed pHGG typically see median progression-free survival (PFS) of about 2.25 months and overall survival (OS) of only 5.6 months—sobering figures that underscore the high unmet need.
Among patients who received at least 55 mCi of iopofosine I 131 (n=6), the average PFS reached 5.4 months and OS climbed to 8.6 months, both ongoing. Disease control was observed in all cases. Notably, three patients who completed additional cycles had average PFS of 8.1 months and OS of 11.5 months (ongoing), with two patients experiencing objective tumor responses. The following table summarizes the trial’s reported outcomes:
| Cohort | Number of Patients | Mean PFS (months) | Mean OS (months) | Objective Responses | Disease Control Rate |
|---|---|---|---|---|---|
| ≥55 mCi Total Dose | 6 | 5.4 | 8.6 | 2/6 | 100% |
| 4+ Infusions | 3 | 8.1 | 11.5 | 2/3 | 100% |
| Historical Data | - | 2.25 | 5.6 | - | - |
Case Studies Illustrate Potential for Lasting Response and Tumor Reduction
The CLOVER-2 study showcased two illustrative patient cases:
- Case 1: A 25-year-old male with diffuse hemispheric glioma, after three prior therapies, saw his tumor shrink by over 50% eight months post-screening. Progression-free survival reached 10.9 months and survival extended beyond 18 months (ongoing).
- Case 2: A 15-year-old female with ependymoma, previously treated with eight different regimens, reduced tumor size from 252 mm2 to 141 mm2 after iopofosine I 131, achieving 11.2 months of PFS and over 17 months of ongoing survival.
Favorable Safety Profile Adds to Therapeutic Appeal
Iopofosine I 131 was generally well-tolerated. Importantly, patients did not experience cardiovascular, liver, or kidney toxicities, nor any peripheral neuropathy or significant bleeding—common challenges in many cancer treatments. The most frequent side effects were hematologic (e.g., thrombocytopenia, neutropenia, anemia) and manageable, with no treatment-related deaths reported. The data suggest selective tumor targeting with minimal impact outside the blood system.
Regulatory Path Could Accelerate Patient Access and Further Collaboration
With the Rare Pediatric Disease Designation, Cellectar becomes eligible—upon a future FDA approval and program reauthorization—to receive a Priority Review Voucher (PRV). These vouchers have been valuable tools, either for accelerating future drug reviews or as assets that can be sold or transferred. Combined with previous orphan and breakthrough designations, iopofosine I 131’s regulatory profile could hasten broader patient access.
Takeaway: Early Signals Point to Promising New Option for Pediatric Brain Tumor Patients
Cellectar’s progress is particularly meaningful in light of the historically poor outcomes for relapsed pediatric high-grade glioma. With survival and disease control data from the ongoing trial exceeding historical standards, iopofosine I 131 may be on the path to address a long-standing unmet need in pediatric oncology. The upcoming milestones and future results from larger trials will be important to watch as the company pushes forward.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI